Selexel
Toulouse
About Selexel
SeleXel is a biotechnology company whose mission is to develop efficient therapeutic solutions in Oncology using a very innovative technology: RNA interference. This natural biological mechanism allows to very specifically impair the synthesis of proteins required for the development of a cancer. SeleXel concentrates its initial efforts on the development of drugs treating prostate cancers that became resistant to conventional hormonal treatments. The company develops a portfolio of siRNAs blocking cancer spreading (metastasis), and restoring the ability of the immune system to eliminate the tumor.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: Less than $1M
- Last round: Series Unknown (May 2005)
- Website: selexel.comen
Industries & Categories
Biotechnology
Canonical: https://fsome.com/organization/selexel-3168523 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.